Insulet Corp (PODD) · Nov 4, 2026 · Earnings

Insulet earnings beat as margins expand and buyback reaches $1B

Beat — Adjusted EPS $1.99 vs ~$1.59 consensus

Insulet earnings beat Q3 expectations, with strong Omnipod growth, wider margins, raised revenue floors, and a new $1 billion buyback.

Insulet is scaling Omnipod as a global tubeless insulin-pump platform while repairing U.S. execution in type 2 diabetes and expanding internationally. The prior setup already included strong growth, but also a reset U.S. outlook after type 2 onboarding and retention problems; Q2 guidance had called for 17.5%-19.5% total Q3 growth and 20%-22% full-year growth.

The quarter clearly beat the published bar. Revenue reached $842.0 million versus roughly $832.6 million expected, while adjusted diluted EPS was $1.99 versus about $1.59 consensus. The beat was not just accounting noise: Omnipod revenue grew 20.0% in constant currency, led by 33.0% international growth, and adjusted operating margin expanded to 22.0% from 17.1% a year earlier.

MetricQ3 2026Q3 2025Consensus / prior guide
Revenue (Financial Statements)$842.0M$706.3M~$832.6M
Adjusted diluted EPS (Non-GAAP results)$1.99$1.24~$1.59
Adjusted operating margin (Non-GAAP results)22.0%17.1%—
Total FY revenue growth (Guidance)21%-22%—20%-22%
Adjusted operating margin expansion (Guidance)~150 bps—~100 bps

Management improved the forward picture, especially outside the U.S. The full-year total-growth range moved from 20%-22% to 21%-22%, while international Omnipod growth rose to 32%-33% from 30%-32%. U.S. Omnipod guidance was narrowed to 17.5%-18.5% from 17%-19%, so the company is not claiming that the type 2 execution issue is fully solved; the more credible change is that international momentum and margin delivery are offsetting that constraint.

The $1 billion buyback reinforces confidence but is not the core operating surprise. Insulet expects to spend about $400 million in the fourth quarter from existing cash, a meaningful capital-allocation shift relative to its $584.4 million cash balance at September 30. It supports the message that cash generation and profitability are becoming durable, but it also leaves less liquidity for other uses; the business impact is secondary to the earnings beat and guidance improvement.

Bottom line: This is a meaningful execution upgrade from the post-reset story: Insulet beat expectations, international growth remained exceptional, and margin guidance improved. The remaining question is U.S. type 2 execution, but this filing strengthens rather than changes the company's existing growth trajectory.

What to watch next

Q4 results and 2027 outlook, early February 2027

Original filing on SEC EDGAR

More Insulet Corp news

Insulet earnings beat as margins expand and buyback reaches $1B | PODD Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.